Test Price
2,800 AED✅ Home Collection Available
MVK Gene Porokeratosis Type 3, Disseminated Superficial Actinic Genetic Test in UAE | 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
GUARANTEE 99.9% Diagnostic Sensitivity – ISO 9001:2015 Certified NGS Workflow (Cert: INT/EGQ/2509DA/3139)
PREMIUM LOGISTICS VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – Available daily 8 AM to 11 PM.
CLINICAL SUPPORT Post-Test Telephonic Clinical Guidance with a DHA-licensed physician.
INSURANCE Direct Billing Verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
This advanced Genetic Test identifies mutations in the MVK gene responsible for Disseminated Superficial Actinic Porokeratosis (DSAP), guiding precise diagnosis, family risk assessment, and personalized management.
Next-Generation Sequencing (NGS) on an Illumina® platform, including full gene coverage and copy number variant analysis, yields 99.9% analytical sensitivity and specificity.
| Feature | Our Test (DNA Labs UAE) | Closest Alternative |
|---|---|---|
| Precision | Full‑gene NGS with copy number analysis; 99.9% analytical sensitivity | Single‑gene Sanger sequencing; limited to point mutations |
| Methodology | Next‑Generation Sequencing (NGS) on Illumina® platform, ISO‑validated | Capillary electrophoresis; lower throughput |
| Turnaround Time | 3–4 weeks with genetic counsellor review | 6–8 weeks; often without dedicated interpretation |
Physician Insight & Safety Protocols
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Card
Medication Caution:
Do not discontinue, adjust, or replace any prescribed medication without direct consultation with your treating physician. Please provide a complete list of all medications and supplements to the phlebotomist before sample collection.
Exclusion Card
SAFETY EXCLUSIONS & RED FLAGS:
- Acute skin infection or open wound at venipuncture site – postpone collection.
- Current hospitalization for severe systemic illness – requires in‑hospital phlebotomy.
- Known bleeding disorder or therapeutic anticoagulation not disclosed – may alter sample integrity.
- If you develop sudden worsening of skin lesions, bleeding, fever, or signs of infection, seek emergency medical care immediately.
Patient FAQ & Clinical Guidance
1. What is the clinical utility of this MVK porokeratosis genetic test?
The MVK genetic test identifies pathogenic variants causing Disseminated Superficial Actinic Porokeratosis (DSAP), enabling accurate diagnosis, cascade family screening, and personalized dermatologic surveillance. This test is used when clinical features suggest DSAP and a positive family history, helping to differentiate it from other porokeratosis variants and to guide genetic counselling. The results also inform reproductive risk estimation and early skin cancer vigilance.
2. How is the sample collected and what preparation is needed?
A simple blood draw is collected by a DHA‑licensed phlebotomist during a home visit. You must complete a mandatory pre‑genetic counselling session to review your clinical history and draw a pedigree chart of affected family members. No fasting is required, but please inform the team of all medications and supplements before collection. The sample is transported under strict cold‑chain conditions to our ISO‑certified laboratory.
3. What do my results mean and how will they be delivered?
A detailed report classifies variants as pathogenic, likely pathogenic, uncertain significance, or benign, accompanied by a clinical interpretation from our genetic team. Results are securely shared via encrypted PDF within 3–4 weeks, followed by a telephonic consultation with a DHA‑licensed physician who explains the implications for you and your relatives. If a variant of uncertain significance (VUS) is found, periodic re‑analysis is recommended as scientific knowledge evolves. The report also includes ICD‑10 coding (L56.5, Z13.79, Z84.8) for insurance purposes.
UAE Regulatory & Data Privacy Adherence
This service complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is processed in accordance with DHA regulations and stored on encrypted servers within the UAE.
Clinical testing safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Your sample and data are handled with the highest confidentiality and security standards.
Clinical & Logistical Metadata
| Test Name | MVK Gene Sequencing – Porokeratosis Type 3 (Disseminated Superficial Actinic) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA), genomic DNA, or FTA card |
| Methodology Used | Next‑Generation Sequencing (NGS) – Illumina® platform, full‑gene & CNV analysis |
| ICD-10-CM Code | L56.5, Z13.79, Z84.8 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | License No. 1143 • Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians